Carlsmed (NASDAQ: CARL) shares preliminary unaudited revenue for 2025 period

Rhea-AI Filing Summary

Carlsmed, Inc. filed a current report to disclose that it has issued a press release announcing its preliminary, unaudited revenue for the year ended December 31, 2025. The company furnished the full text of this press release as Exhibit 99.1, stating that it is incorporated by reference in the report but will not be treated as filed for liability purposes under the Exchange Act. The filing also notes that Carlsmed’s common stock trades on The Nasdaq Stock Market LLC under the symbol CARL.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001794546false00017945462026-01-122026-01-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

Carlsmed, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-42756	83-1081863
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
1800 Aston Ave, Suite 100
Carlsbad, California				92008
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (760) 766-1923

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value per share		CARL		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02 Results of Operations and Financial Condition.

On January 12, 2026, the Company issued a press release announcing its preliminary and unaudited revenue for the year ended December 31, 2025. The full text of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

The foregoing information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(a) Exhibits

Exhibit No.		Description
99.1*		Press Release of Carlsmed, Inc., dated January 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CARLSMED, INC.
Date: January 12, 2026	By:	/s/Michael Cordonnier
		Michael Cordonnier Chief Executive Officer and President

FAQ

What did Carlsmed (CARL) disclose in this 8-K filing?

Carlsmed, Inc. reported that it issued a press release announcing its preliminary and unaudited revenue for the year ended December 31, 2025, and furnished that release as Exhibit 99.1.

Which period does Carlsmed’s preliminary revenue disclosure cover?

The preliminary and unaudited revenue disclosed by Carlsmed covers the year ended December 31, 2025.

Where can investors find the detailed preliminary revenue information for Carlsmed (CARL)?

The detailed preliminary revenue information is contained in Carlsmed’s press release furnished as Exhibit 99.1 to the report and incorporated by reference.

Is Carlsmed’s preliminary revenue press release considered filed for liability purposes?

No. The company states that the information in Item 2.02, including Exhibit 99.1, is furnished and will not be deemed filed for purposes of Section 18 of the Exchange Act.

What exchange is Carlsmed (CARL) common stock listed on?

Carlsmed’s common stock, with a par value of $0.00001 per share, is listed on The Nasdaq Stock Market LLC under the symbol CARL.

Who signed the Carlsmed 8-K related to preliminary revenue?

The report was signed on behalf of Carlsmed, Inc. by Michael Cordonnier, who serves as Chief Executive Officer and President.